Summary Of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2022

The following table summarizes our net revenue disaggregated by segment, product and region (in thousands):


	Three Months Ended March 31,				Nine Months Ended March 31,
	2022		2021		2022		2021
U.S., Canada and Latin America
Devices	$	250,768	$	192,897	$	771,475	$	595,287
Masks and other	224,665		209,984		681,803		637,507
Total Sleep and Respiratory Care	$	475,433	$	402,881	$	1,453,278	$	1,232,794
Software as a Service	101,142		93,836		297,693		277,813
Total	$	576,575	$	496,717	$	1,750,971	$	1,510,607
Combined Europe, Asia and other markets
Devices	$	182,307	$	172,838	$	608,268	$	536,856
Masks and other	105,618		99,212		304,151		273,259
Total Sleep and Respiratory Care	$	287,925	$	272,050	$	912,419	$	810,115
Global revenue
Devices	$	433,075	$	365,735	$	1,379,743	$	1,132,143
Masks and other	330,283		309,196		985,954		910,766
Total Sleep and Respiratory Care	$	763,358	$	674,931	$	2,365,697	$	2,042,909
Software as a Service	101,142		93,836		297,693		277,813
Total	$	864,500	$	768,767	$	2,663,390	$	2,320,722

The following table summarizes our contract balances (in thousands):


	March 31, 2022		June 30, 2021		Balance sheet caption
Contract assets
Accounts receivable, net	$	508,580	$	614,292	Accounts receivable, net
Unbilled revenue, current	25,653		10,893		Prepaid expenses and other current assets
Unbilled revenue, non-current	7,018		6,214		Prepaid taxes and other non-current assets

Contract liabilities
Deferred revenue, current	(112,449)		(109,611)		Deferred revenue (current liabilities)
Deferred revenue, non-current	(94,094)		(91,496)		Deferred revenue (non-current liabilities)

The components of lease revenue were as follows (in thousands):